Literature DB >> 23148181

Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes.

Alaa E El-Sisi1, Sahar K Hegazy, Shereen S Metwally, Alaa M Wafa, Naglaa A Dawood.   

Abstract

OBJECTIVE: This study investigated the possibility that genetic factors, such as polymorphism of K inward rectifier subunit (Kir6.2), E23K, and Arg(972) polymorphism of insulin receptor sub-strate-1 (IRS-1), may predispose patients to sulfonylurea failure.
METHODS: A total of 100 unrelated Egyptian patients with type 2 diabetes were recruited. They were divided into two equal groups: group I consisted of patients with secondary failure to sulfonylurea (hemoglobin A(1c) ≥ 8% despite sulfonylurea therapy) while group II consisted of patients whose condition was controlled with oral therapy.
RESULTS: Of all the patients, 45% and 14% were carriers of the K allele and Arg(972) variants respectively. The frequency of the K allele was 34% among patients with diabetes that was controlled with oral therapy and 56% among patients with secondary failure to sulfonylurea. The frequency of the Arg(972) IRS-1 variant was 6% among patients with diabetes controlled with oral therapy and 22% among patients with secondary failure.
CONCLUSION: The E23K variant of the Kir6.2 gene and Arg(972) IRS-1 variants are associated with increased risk for secondary failure to sulfonylurea.

Entities:  

Keywords:  Arg972 IRS-1 variant; E23K polymorphism; IRS-1; KCNJ11; Kir6.2; sulfonylurea failure

Year:  2011        PMID: 23148181      PMCID: PMC3474636          DOI: 10.1177/2042018811415985

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  50 in total

1.  The 31-cM region of chromosome 11 including the obesity gene tubby and ATP-sensitive potassium channel genes, SUR1 and Kir6.2, does not contain a major susceptibility locus for NIDDM in 127 non-Hispanic white affected sibships.

Authors:  T Lindner; C Gragnoli; J Schulze; H Rietzsch; C Petzold; H E Schröder; N J Cox; G I Bell
Journal:  Diabetes       Date:  1997-07       Impact factor: 9.461

2.  Enzymatic determination of total serum cholesterol.

Authors:  C C Allain; L S Poon; C S Chan; W Richmond; P C Fu
Journal:  Clin Chem       Date:  1974-04       Impact factor: 8.327

3.  The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance.

Authors:  M G Baroni; M Arca; F Sentinelli; R Buzzetti; F Capici; S Lovari; M Vitale; S Romeo; U Di Mario
Journal:  Diabetologia       Date:  2001-03       Impact factor: 10.122

4.  Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1.

Authors:  H Abe; N Yamada; K Kamata; T Kuwaki; M Shimada; J Osuga; F Shionoiri; N Yahagi; T Kadowaki; H Tamemoto; S Ishibashi; Y Yazaki; M Makuuchi
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism.

Authors:  A Nestorowicz; N Inagaki; T Gonoi; K P Schoor; B A Wilson; B Glaser; H Landau; C A Stanley; P S Thornton; S Seino; M A Permutt
Journal:  Diabetes       Date:  1997-11       Impact factor: 9.461

6.  The Gly972-->Arg IRS-1 variant is associated with type 1 diabetes in continental Italy.

Authors:  Massimo Federici; Antonio Petrone; Ottavia Porzio; Carla Bizzarri; Davide Lauro; Rossella D'Alfonso; Ippolita Patera; Marco Cappa; Lorenza Nisticò; Marco Baroni; Giorgio Sesti; Umberto di Mario; Renato Lauro; Raffaella Buzzetti
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

7.  Identification of microsatellite markers near the human genes encoding the beta-cell ATP-sensitive K+ channel and linkage studies with NIDDM in Japanese.

Authors:  N Iwasaki; M Kawamura; K Yamagata; N J Cox; S Karibe; H Ohgawara; N Inagaki; S Seino; G I Bell; Y Omori
Journal:  Diabetes       Date:  1996-02       Impact factor: 9.461

8.  Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.

Authors:  P Fossati; L Prencipe
Journal:  Clin Chem       Date:  1982-10       Impact factor: 8.327

9.  The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia.

Authors:  Otto Tschritter; Michael Stumvoll; Fausto Machicao; Martin Holzwarth; Melanie Weisser; Elke Maerker; Anna Teigeler; Hans Häring; Andreas Fritsche
Journal:  Diabetes       Date:  2002-09       Impact factor: 9.461

10.  The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets.

Authors:  M Federici; M L Hribal; M Ranalli; L Marselli; O Porzio; D Lauro; P Borboni; R Lauro; P Marchetti; G Melino; G Sesti
Journal:  FASEB J       Date:  2000-11-14       Impact factor: 5.191

View more
  7 in total

Review 1.  Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.

Authors:  N K Loganadan; H Z Huri; S R Vethakkan; Z Hussein
Journal:  Pharmacogenomics J       Date:  2016-01-26       Impact factor: 3.550

2.  MIR4532 gene variant rs60432575 influences the expression of KCNJ11 and the sulfonylureas-stimulated insulin secretion.

Authors:  Zhang-Ren Chen; Fa-Zhong He; Mou-Ze Liu; Jin-Lei Hu; Heng Xu; Hong-Hao Zhou; Wei Zhang
Journal:  Endocrine       Date:  2018-09-21       Impact factor: 3.633

3.  KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.

Authors:  Jingwen Song; Yunzhong Yang; Franck Mauvais-Jarvis; Yu-Ping Wang; Tianhua Niu
Journal:  BMC Med Genet       Date:  2017-06-06       Impact factor: 2.103

Review 4.  Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.

Authors:  Gaia Chiara Mannino; Francesco Andreozzi; Giorgio Sesti
Journal:  Diabetes Metab Res Rev       Date:  2019-01-07       Impact factor: 4.876

Review 5.  KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus.

Authors:  Polin Haghvirdizadeh; Zahurin Mohamed; Nor Azizan Abdullah; Pantea Haghvirdizadeh; Monir Sadat Haerian; Batoul Sadat Haerian
Journal:  J Diabetes Res       Date:  2015-09-13       Impact factor: 4.011

6.  Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients.

Authors:  Goljahan Soltani; Zahra Hatefi; Ahmad Reza Salehi; Sharifeh Khosravi; Moosa Rahimi Ghiasi; Keimer Teke; Ashraf Aminorroaya; Rasoul Salehi
Journal:  Adv Biomed Res       Date:  2018-06-25

Review 7.  Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.

Authors:  Yulia A Nasykhova; Ziravard N Tonyan; Anastasiia A Mikhailova; Maria M Danilova; Andrey S Glotov
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.